Biodesix CEO Scott Hutton Named to The Healthcare Technology Report’s List of Top 25 Biotech CEOs in 2022
22 2월 2022 - 8:00PM
Business Wire
Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic
solutions company with a focus in lung disease, today announced
that its Chief Executive Officer was named in The Healthcare
Technology Report’s list of Top 25 Biotech CEOs of 2022. The annual
list recognizes the most accomplished executives in the biotech
industry.
An extensive process was run to evaluate the hundreds of CEOs
who were nominated this year. These CEOs lead exemplary
organizations in the fields of gene therapy to vaccine development,
cancer treatment, proteomics, diagnostics, mRNA-based therapeutics,
and other related areas. Read the full report here.
Hutton’s profile provides insight as to how his personal
leadership philosophy emphasizes ‘helping people, giving back, and
positively impacting and improving people’s health and lives’.
Under his direction and leadership, Biodesix has grown into a
leading patient-centric lung disease diagnostics company with a
mission to unite biopharma, physicians, and patients to transform
the standard of care and improve outcomes with personalized
diagnostics.
“I am honored to be named as a leading CEO in The Healthcare
Technology Report and included on a list with so many resilient,
entrepreneurial industry leaders who are making a meaningful impact
on patients,” said Hutton. “The recognition also highlights the
commitment and work that the entire team at Biodesix accomplishes
every day to impact patients with critical diseases.”
About Biodesix
Biodesix is a leading data-driven diagnostic solutions company
with a focus in lung disease. The Company develops diagnostic tests
addressing important clinical questions by combining multi-omics
through the power of artificial intelligence. Biodesix is the first
company to offer eight non-invasive tests for patients with lung
diseases. The blood based Nodify Lung® nodule risk assessment
testing strategy, consisting of the Nodify XL2® and the Nodify CDT®
tests, evaluates the risk of malignancy in incidental pulmonary
nodules, enabling physicians to better triage patients to the most
appropriate course of action. The blood based IQLung™ strategy for
lung cancer patients integrates the GeneStrat® targeted test, the
GeneStrat NGS™ test and the VeriStrat® test to support treatment
decisions across all stages of lung cancer with results in an
unprecedented 36-72 hours, expediting time to treatment. Biodesix
also leverages the proprietary and advanced Diagnostic Cortex® AI
(Artificial Intelligence) platform, to collaborate with many of the
world’s leading biotechnology and pharmaceutical companies to solve
complex diagnostic challenges in lung disease. Biodesix launched
the SARS-CoV-2 ddPCR™ test, the Platelia SARS-CoV-2 Total Ab, and
the cPass™ SARS-CoV-2 Neutralization Antibody test (cPass™
Neutralization Test Kit, GenScript, Inc,) in response to the global
pandemic and virus that impacts the lung and causes COVID-19. For
more information about Biodesix, visit biodesix.com.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements contained in this press release other
than statements of historical fact, are forward-looking statements.
The words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,”
“opportunity,” “goals,” or “should,” and similar expressions are
intended to identify forward-looking statements. Such statements
are based on management’s current expectations and involve risks
and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors. Biodesix has based these
forward-looking statements largely on its current expectations and
projections about future events and trends. These forward-looking
statements are subject to a number of risks, uncertainties, and
assumptions. Forward-looking statements may include information
concerning the impact of the COVID-19 pandemic on Biodesix and its
operations, it is possible or assumed future results of operations,
including descriptions of its revenues, profitability, outlook, and
overall business strategy. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. The Company's ability to continue as a
going concern could cause actual results to differ materially from
those contemplated in this press release and additionally, other
factors that could cause actual results to differ materially from
those contemplated in this press release can be found in the Risk
Factors section of Biodesix’s most recent annual report on Form
10-K, filed March 16, 2021, or subsequent quarterly reports on Form
10-Q during 2021, if applicable. Biodesix undertakes no obligation
to revise or publicly release the results of any revision to such
forward-looking statements, except as required by law. Given these
risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220222005131/en/
Media: Bobbi Coffin bobbi.coffin@biodesix.com (303) 892-3203
Investors: Chris Brinzey chris.brinzey@westwicke.com (339)
970-2843
Biodesix (NASDAQ:BDSX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Biodesix (NASDAQ:BDSX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024